Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | May 24, 2017 | May 25, 2017 |
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | Director · CHAIRMAN & CEO | September 01, 2026 | September 03, 2026 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | June 08, 2017 | September 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date May 24, 2017 · Filed May 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $5.13 · Expires 2027-05-24 | Direct | 30,000 |
Reported balance
After 2017-05-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-24 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning June 24, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning June 24, 2017.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 86,165 |
Reported balance
After 2026-09-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-01 · Exercise / conversion · Acquired 9,991 · Balance 86,165 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,646 |
Reported balance
After 2026-09-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-01 · Exercise / conversion · Acquired 6,481 · Balance 92,646 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 98,883 |
Reported balance
After 2026-09-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-09-01 · Exercise / conversion · Acquired 6,237 · Balance 98,883 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 107,492 |
Reported balance
After 2026-09-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-09-01 · Exercise / conversion · Acquired 8,609 · Balance 107,492 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Patel Family Irrevocable Trust of 2025 | 92,348 |
Reported balance
After 2026-09-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-09-01 · Tax withholding · Disposed 15,144 · Balance 92,348 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 30,050 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 30,050 · Balance 30,050 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 25,826 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 8,609 · Balance 25,826 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 12,475 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 6,237 · Balance 12,475 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,481 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 6,481 · Balance 6,481 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 9,991 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 120,150 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 120,150 · Balance 120,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016 | 109,795 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 109,795 |
| Class A Ordinary ShareSEC Table I · non-derivative | IndirectHeld by The Anglia 2013 Revocable Trust, u/d/t August 15, 2013 | 51,794 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 51,794 |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Syros Pharmaceuticals, Inc.
Report date June 08, 2017 · Filed September 22, 2017 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2027-06-07 | Direct | 11,000 |
Reported balance
After 2017-06-08 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2017-06-08 · Grant · Acquired 11,000 · Balance 11,000 F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person. F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date.
F2: This amendment to the Statement of Changes in Beneficial Ownership of Securities on Form 4 filed with the Securities and Exchange Commission on June 12, 2017 is being filed to correct a typographical error in the exercise price of the option to purchase Common Stock held by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 60,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,100 Underlying: Class A Ordinary Share · 60,100 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee. F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 30,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,050 Underlying: Class A Ordinary Share · 30,050 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 120,150 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · derivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,150 Underlying: Class A Ordinary Share · 120,150 shares Expires 2036-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 10,313 | $48.13 | $496,364.69 |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 71,014 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 21,327 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001532218-26-000002 · form4-04032026_080457.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 81,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-25-000007 · form4-11142025_091149.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Patel Family Irrevocable Trust of 2025 Disclosed balance after: 60,000 Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-25-000007 · form4-11142025_091149.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Anglia 2013 Revocable Trust Disclosed balance after: 51,794 Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 111,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-25-000007 · form4-11142025_091149.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by The Anglia 2013 Revocable Trust Disclosed balance after: 111,794 Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GiftClass A Ordinary Share | 111,794 | $0.00 | $0.00 |
DisclosureSEC source: 0001532218-25-000007 · form4-11142025_091149.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| October 22, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 97,390 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · derivative · entry 11 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 97,390 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 22, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 97,390 | $38.83 | $3,781,653.70 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 7 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,794 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.495 and $39.255. The price reported in this column reflects a weighted sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 22, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 97,390 | $3.80 | $370,082.00 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 209,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 39,331 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,390 Underlying: Class A Ordinary Share · 39,331 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 39,331 | $38.77 | $1,524,862.87 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,794 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.49 and $39.235. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 21, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 39,331 | $3.80 | $149,457.80 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 121,248 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,721 Underlying: Class A Ordinary Share · 121,248 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 22,314 | $39.32 | $877,386.48 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,794 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.14 and $39.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 98,934 | $38.81 | $3,839,628.54 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,108 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $38.14 and $39.135. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 20, 2025 Filed Oct 22, 2025 21:09 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 121,248 | $3.80 | $460,742.40 |
DisclosureSEC source: 0001532218-25-000005 · form4-10222025_091005.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 233,042 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 7, 2025. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 13 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 6,569 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 3,177 | $34.28 | $108,907.56 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,794 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 9,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 12 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,991 Underlying: Class A Ordinary Share · 9,992 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 11 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,962 Underlying: Class A Ordinary Share · 6,481 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 6,238 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,712 Underlying: Class A Ordinary Shares · 6,238 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 137,638 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,638 Underlying: Class A Ordinary Share · 137,638 shares Expires 2035-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 34,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,435 Underlying: Class A Ordinary Share · 34,435 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 10,983 | $33.49 | $367,820.67 |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,402 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 9,992 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,385 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,481 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:44 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,238 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023550 · form4-09032025_080927.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| May 28, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 62,116 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 62,116 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 28, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 62,116 | $27.33 | $1,697,630.28 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 28, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 62,116 | $1.59 | $98,764.44 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 27, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 19,317 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,116 Underlying: Class A Ordinary Share · 19,317 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 27, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 19,317 | $27.01 | $521,752.17 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.06. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 27, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 19,317 | $1.59 | $30,714.03 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 3 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 4,837 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · derivative · entry 8 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,433 Underlying: Class A Ordinary Share · 4,837 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 4,837 | $27.00 | $130,599.00 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 23, 2025 Filed May 28, 2025 21:25 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 4,837 | $1.59 | $7,690.83 |
DisclosureSEC source: 0001415889-25-014744 · form4-05282025_050501.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,349 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-014167 · form4-05222025_080524.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,270 Underlying: Class A Ordinary Share · 2,349 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,349 | $27.02 | $63,469.98 |
DisclosureSEC source: 0001415889-25-014167 · form4-05222025_080524.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:38 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,349 | $1.59 | $3,734.91 |
DisclosureSEC source: 0001415889-25-014167 · form4-05222025_080524.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,872 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-013170 · form4-05152025_080533.xml · derivative · entry 4 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,619 Underlying: Class A Ordinary Share · 2,872 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 2,872 | $27.03 | $77,630.16 |
DisclosureSEC source: 0001415889-25-013170 · form4-05152025_080533.xml · nonDerivative · entry 2 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.00 and $27.06. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:39 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,872 | $1.59 | $4,566.48 |
DisclosureSEC source: 0001415889-25-013170 · form4-05152025_080533.xml · nonDerivative · entry 1 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 09, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 6,029 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 10 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,491 Underlying: Class A Ordinary Share · 6,029 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 09, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 6,029 | $27.05 | $163,084.45 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 6 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,674 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $27.03 and $27.14. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 09, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,029 | $1.59 | $9,586.11 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · nonDerivative · entry 5 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. Read SEC document |
| May 08, 2025 Filed May 9, 2025 21:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 101 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-25-012571 · form4-05092025_090511.xml · derivative · entry 9 Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,520 Underlying: Class A Ordinary Share · 101 shares Expires 2025-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 25, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.